Bladder Cancer
Conditions
Brief summary
To evaluate the effectiveness of the PhageTech Virus BioResistor to detect bladder cancer biomarkers.
Detailed description
This study will sample urine provided by bladder cancer patients as part of their normal routine surveillance screening. No additional effort will be required from the patients and only modest additional effort from the study staff. Some de-identified patient medical information may also be requested, including concominant medications, relevant current or previous diseases, prior bladder cancer interventions and other relevant information to ensure there are no interfering substances or other confounders that could affect study results. There is no risk to patients as the normal diagnostics for bladder cancer will be followed.
Interventions
None listed
Sponsors
PhageTech, Inc.
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Male and female patients ≥ 18 years 2. Previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy 3. Patients with suspected bladder tumor undergoing surveillance cystoscopy 4. Patients must provide written Informed Consent.
Exclusion criteria
1. Patients unable or unwilling to sign the informed consent 2. Age \< 18 years 3. Known HIV/HCV/HBV (information from clinical history).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Successful identification of bladder tumor biomarkersBiomarkers in Patients Under Active BCa Surveillance | Up to 1 year |
Countries
United States
Contacts
Primary ContactRodney Brenneman
Outcome results
None listed